FIND and BD Combine International Efforts to Improve Rapid Tuberculosis Diagnosis for HIV-positive Patients in Developing Countries

Mike Meehan (BD) and Giorgio Roscigno (FIND)

FIND (Foundation for Innovative New Diagnostics) and BD (Becton, Dickinson and Company) (NYSE: BDX) today announced an international collaboration aimed at improving diagnosis of pulmonary tuberculosis (TB) in HIV-infected patients in developing countries.

Today, TB is the leading cause of death in AIDS patients in high-burdened countries, mainly in sub-Saharan Africa. TB is particularly difficult to diagnose in AIDS patients because they often have few or no TB bacteria in their sputum; thus, the standard diagnostic procedure using microscopy is insensitive. Classical culture methods for TB are more sensitive, but notoriously slow, typically requiring 21 to 42 days. BD has developed an improved culture method, the BD MGIT^TM (Mycobacteria Growth Indicator Tube) system, which provides results within 10 to 14 days. The BD MGIT technology can be used both for detection of the bacteria causing TB as well as for the determination of resistance to the TB drugs routinely used for treatment. The BD MGIT system is now widely used in industrialized countries but not in the developing world.

Ed Ludwig, Chairman, President and Chief Executive Officer, BD, said, “BD is committed to providing technologies which can help alleviate the impact of TB and HIV globally. BD is pleased to enter into this agreement with FIND, which is aimed at making these technologies more accessible to the public health sector of high-burdened countries. ”

"Access to quality diagnostic equipment in countries with limited health resources will improve the management of tuberculosis in HIV positive patients,” said Dr. Mario Raviglione, Director of the World Health Organization (WHO) Stop TB Department. “This new agreement provides a blueprint for modern TB technology to be made more widely available globally, which will help reduce TB deaths and decrease transmission rates in high risk areas.”

The agreement between FIND and BD will operate in two stages.

Demonstration Projects

First, FIND will perform and support projects using certain BD equipment, reagents, training and support to be purchased from BD in an effort to demonstrate the effectiveness of more rapid and accurate TB diagnosis in settings where TB and HIV are common and in areas with high prevalence of multiple drug resistant TB. FIND will conduct these projects in close cooperation with WHO, the relevant working groups of the Stop TB Partnership, and the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE) based at the Johns Hopkins Center for TB Research. The goal of these demonstration projects is to promote the use of this technology by national TB control and AIDS programs.

According to Dr. G. Roscigno, CEO of FIND, “The collaboration with BD in the MGIT project is a significant and innovative step forward for FIND. FIND’s demonstration projects using the BD MGIT technology will pave the way for the introduction of critical technologies in the public health sector of developing countries while contributing to a reduction in mortality particularly in HIV / TB patients.”

Implementation

The second stage is focused on sustainable implementation of this advanced diagnostic technology in the public health sector. Under this agreement, BD has committed to provide certain equipment, reagents, training and support to the public health sector in the high-burdened countries on terms which will enable them to be purchased and implemented on a sustainable basis.

Helene Gayle, President of the International AIDS Society (IAS) and Director, HIV, TB and Reproductive Health Program at the Bill and Melinda Gates Foundation said, “We are particularly pleased that this innovative collaboration between BD and FIND is addressing one of the most urgent needs of the TB and HIV community in the developing world.”

About FIND

FIND is the only non-profit organization dedicated solely to the development of diagnostic tests for infectious diseases in developing countries. FIND was established with funding from the Bill and Melinda Gates Foundation. Driven by the huge burden of disease, the existence of global control strategies and the capacity to treat detected cases, FIND has selected tuberculosis as an initial disease focus.

About BD

BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. For the fiscal year ended September 30, 2004, BD reported total revenues of $4.935 billion.

This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, cash flows, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BD website: www.bd.com

BD Public Relations: Barbara Kalavik